Last reviewed · How we verify
Mirdametinib and Carbamazepine
Mirdametinib and Carbamazepine is a Small molecule drug developed by SpringWorks Therapeutics, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Mirdametinib and Carbamazepine |
|---|---|
| Sponsor | SpringWorks Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirdametinib and Carbamazepine CI brief — competitive landscape report
- Mirdametinib and Carbamazepine updates RSS · CI watch RSS
- SpringWorks Therapeutics, Inc. portfolio CI
Frequently asked questions about Mirdametinib and Carbamazepine
What is Mirdametinib and Carbamazepine?
Mirdametinib and Carbamazepine is a Small molecule drug developed by SpringWorks Therapeutics, Inc..
Who makes Mirdametinib and Carbamazepine?
Mirdametinib and Carbamazepine is developed by SpringWorks Therapeutics, Inc. (see full SpringWorks Therapeutics, Inc. pipeline at /company/springworks-therapeutics-inc).
What development phase is Mirdametinib and Carbamazepine in?
Mirdametinib and Carbamazepine is in Phase 1.